Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 184

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Prognostic Utility of Cell Cycle Progression Score in Men With Prostate Cancer After Primary External Beam Radiation Therapy

Open access
Freedland, Stephen J., Gerber, Leah, Reid, Julia, Welbourn, William, Tikishvili, Eliso, Park, Jimmy, Younus, Adib, Gutin, Alexander, Sangale, Zaina, Lanchbury, Jerry S., Salama, Joseph K., Stone, Steven·2013·International Journal of Radiation Oncology*Biology*Physics

Abstract

Purpose The cell cycle progression (CCP) score, a prognostic RNA signature based on the average expression level of 31 CCP genes, has been shown to predict biochemical recurrence (BCR) after prostatectomy and prostate cancer specific mortality in men undergoing observation. However, the value of the CCP score in men who received primary external beam radiation therapy (EBRT) is untested. Methods and Materials The CCP score was derived retrospectively from diagnostic biopsy specimens of men diagnosed with prostate cancer from 1991 to 2006 (n=141). All patients were treated with definitive EBRT; approximately half of the cohort was African-American. Outcome was time from EBRT to BCR using the Phoenix definition. Median follow-up for patients without BCR was 4.8 years. Association with outcome was evaluated by CoxPH survival analysis and likelihood ratio tests. Results Of 141 patients, 19 (13%) had BCR. The median CCP score for patient samples was 0.12. In univariable analysis, CCP score significantly predicted BCR (p-value = 0.0017). The hazard ratio (HR) for BCR was 2.55 for a one-unit increase in CCP score (equivalent to a doubling of gene expression). In a multivariable analysis with Gleason score, PSA, percent positive cores, and androgen deprivation therapy, the HR for CCP remained significant (p-value = 0.034), indicating that CCP provides prognostic information that is not provided by standard clinical parameters. With 10-year censoring, the CCP score was associated with prostate cancer specific mortality (p-value = 0.013). There was no evidence for interaction between CCP and any clinical variable, including ethnicity. Conclusions Among men treated with EBRT, the CCP score significantly predicated outcome and provided greater prognostic information than was available with clinical parameters. If validated in a larger cohort, CCP score could identify high-risk men undergoing EBRT who may need more aggressive therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ijrobp.2013.04.043

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 184

Metadata

Authors
Freedland, S. J., Gerber, L., Reid, J., Welbourn, W., Tikishvili, E., Park, J., Younus, A., Gutin, A., Sangale, Z., Lanchbury, J. S., Salama, J. K., & Stone, S.
Venue
International Journal of Radiation Oncology*Biology*Physics
Publisher
Elsevier BV
Published
2013-08
Volume
86
Issue
5
Pages
848-853
ISSN
0360-3016 (ISSN-L)
OpenAlex
W2009101549
Cited by
184
References
1
FWCI
16.32
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prognostic Utility of Cell Cycle Progression Score in Men With Prostate Cancer After Primary External Beam Radiation Therapy. https://app.cochat.ai/papers/10.1016/j.ijrobp.2013.04.043
The paper
Freedland, S. J., Gerber, L., Reid, J., Welbourn, W., Tikishvili, E., Park, J., Younus, A., Gutin, A., Sangale, Z., Lanchbury, J. S., Salama, J. K., & Stone, S. (2013). Prognostic Utility of Cell Cycle Progression Score in Men With Prostate Cancer After Primary External Beam Radiation Therapy. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2013.04.043

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.